Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 5/2018

01-09-2018 | Original Article

Family history of cancer in first-degree relatives and risk of gastric cancer and its precursors in a Western population

Authors: Minkyo Song, M. Constanza Camargo, Stephanie J. Weinstein, Ana F. Best, Satu Männistö, Demetrius Albanes, Charles S. Rabkin

Published in: Gastric Cancer | Issue 5/2018

Login to get access

Abstract

Background

Family history may inform risks of gastric cancer and preneoplastic lesions.

Methods

We examined associations with history of cancer in first-degree relatives for 307 incident gastric cancer cases among 20,720 male smokers in a prospective study in Finland. Cox regression was used to calculate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI). Logistic regression was used to estimate odds ratios (OR) and 95% CIs for low serum pepsinogen, a marker of gastric atrophy.

Results

Gastric cancer risk was associated with gastric cancer history in first-degree relatives overall (HR 1.56, 95% CI 1.15–2.12), in fathers (HR 1.67, 95% CI 1.09–2.55) and in siblings (HR 2.05, 95% CI 1.25–3.38). Associations were significant for noncardia (HR 1.83, 95% CI 1.30–2.57) but not cardia (HR 0.93, 95% CI 0.46–1.87) cancers, and marginal for both intestinal—(HR 1.53, 95% CI 0.92–2.55) and diffuse-type (HR 1.47, 95% CI 0.72–3.03) histologies. Family history of other cancer types was not associated with gastric cancer risk. Family history of gastric cancer was associated with low pepsinogen (OR 1.29, 95% CI 1.11–1.50).

Conclusions

Family history of gastric cancer is strongly associated with specific subtypes of gastric cancer as well as with gastric atrophy, a risk factor for developing this malignancy.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
2.
3.
Song M, Lee H, Kang D. Epidemiology and screening of gastric cancer in Korea. J Korean Med Assoc. 2015;58(3):183–90.CrossRef
4.
5.
Botterweck AA, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29(4):645–54.CrossRefPubMed
6.
Song M, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer. 2015;18(3):580–9.CrossRefPubMed
7.
Shen L, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535–47.CrossRefPubMed
8.
9.
Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 2009;15(22):2689–92.CrossRefPubMedPubMedCentral
10.
Yoon PW, et al. Can family history be used as a tool for public health and preventive medicine? Genet Med. 2002;4(4):304–10.CrossRefPubMed
11.
Guttmacher AE, Collins FS, Carmona RH. The family history-more important than ever. N Engl J Med. 2004;351(22):2333–6.CrossRefPubMed
12.
Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer. 2010;102(2):237–42.CrossRefPubMed
13.
The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol. 1994;4(1):1–10.
14.
Korhonen P, et al. The Finnish Cancer Registry as follow-up source of a large trial cohort–accuracy and delay. Acta Oncol. 2002;41(4):381–8.CrossRefPubMed
15.
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed
16.
Varis K, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol. 2000;35(9):950–6.CrossRefPubMed
17.
Wang M, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782–800.CrossRefPubMed
18.
19.
20.
Charvat H, et al. Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II. Int J Cancer. 2016;138(2):320–31.CrossRefPubMed
21.
Yatsuya H, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case–control study. Br J Cancer. 2004;91(5):929–34.CrossRefPubMedPubMedCentral
22.
Vieira AR, et al. Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR continuous update project. Ann Oncol. 2017;28(8):1788–802.CrossRefPubMed
23.
Fitzgerald RC, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–44.CrossRefPubMedPubMedCentral
24.
Pharoah PD, et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.CrossRefPubMed
25.
Dhillon PK, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer. 2001;93(1):148–52.CrossRefPubMed
26.
Safaee A, et al. Family history of cancer and risk of gastric cancer in Iran. Asian Pac J Cancer Prev. 2011;12(11):3117–20.PubMed
27.
Foschi R, et al. Family history of cancer and stomach cancer risk. Int J Cancer. 2008;123(6):1429–32.CrossRefPubMed
28.
Eto K, et al. Familial clustering in subgroups of gastric cancer stratified by histology, age group and location. Eur J Surg Oncol. 2006;32(7):743–8.CrossRefPubMed
29.
Bakir T, et al. Gastric cancer and other organ cancer history in the parents of patients with gastric cancer. Eur J Cancer Prev. 2003;12(3):183–9.CrossRefPubMed
30.
Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case–control study. Cancer Sci. 2003;94(6):540–7.CrossRefPubMed
31.
Lissowska J, et al. Family history and risk of stomach cancer in Warsaw, Poland. Eur J Cancer Prev. 1999;8(3):223–7.CrossRefPubMed
32.
Inoue M, et al. Family history and subsite of gastric cancer: data from a case-referent study in Japan. Int J Cancer. 1998;76(6):801–5.CrossRefPubMed
33.
Gajalakshmi CK, Shanta V. Lifestyle and risk of stomach cancer: a hospital-based case–control study. Int J Epidemiol. 1996;25(6):1146–53.CrossRefPubMed
34.
La Vecchia C, et al. Family history and the risk of stomach and colorectal cancer. Cancer. 1992;70(1):50–5.CrossRefPubMed
35.
Turati F, et al. Family history of cancer and the risk of cancer: a network of case–control studies. Ann Oncol. 2013;24(10):2651–6.CrossRefPubMed
36.
Huang X, et al. Effect of life styles on the risk of subsite-specific gastric cancer in those with and without family history. J Epidemiol. 1999;9(1):40–5.CrossRefPubMed
37.
Palli D, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3(1):15–8.PubMed
38.
Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol. 2009;104(1):182–9.CrossRefPubMed
39.
Shin CM, et al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol. 2010;44(2):e34–9.CrossRefPubMed
40.
Garcia-Gonzalez MA, et al. Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a nationwide multicenter study in Spain. Am J Gastroenterol. 2007;102(9):1878–92.CrossRefPubMed
41.
42.
Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol. 1971;106(4):962–8.PubMed
43.
Samloff IM, et al. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982;83(1 Pt 2):204–9.PubMed
44.
Ren JS, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut. 2009;58(5):636–42.CrossRefPubMedPubMedCentral
45.
Di Mario F, et al. ‘Serological biopsy’ in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol. 2003;38(12):1223–7.CrossRefPubMed
46.
Adamu MA, et al. Incidence and risk factors for the development of chronic atrophic gastritis: five year follow-up of a population-based cohort study. Int J Cancer. 2011;128(7):1652–8.CrossRefPubMed
47.
Nishizawa T, et al. Family history is an independent risk factor for the progression of gastric atrophy among patients with Helicobacter pylori infection. United Eur Gastroenterol J. 2017;5(1):32–6.CrossRef
48.
Wang JT, et al. Direct DNA amplification and restriction pattern analysis of Helicobacter pylori in patients with duodenal ulcer and their families. J Infect Dis. 1993;168(6):1544–8.CrossRefPubMed
49.
Blecker U, et al. Evolution of Helicobacter pylori positivity in infants born from positive mothers. J Pediatr Gastroenterol Nutr. 1994;19(1):87–90.CrossRefPubMed
50.
51.
Gold BD, et al. Helicobacter pylori acquisition in infancy after decline of maternal passive immunity. Pediatr Res. 1997;41(5):641–6.CrossRefPubMed
52.
Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA. 2004;292(12):1480–9.CrossRefPubMed
53.
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods, vol. xix. Belmont: Lifetime Learning Publications; 1982. p. 529.
54.
Oliveira C, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):e60–70.CrossRefPubMed
55.
McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74.CrossRefPubMed
56.
Sereno M, et al. Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clin Transl Oncol. 2011;13(9):599–610.CrossRefPubMed
Metadata
Title
Family history of cancer in first-degree relatives and risk of gastric cancer and its precursors in a Western population
Authors
Minkyo Song
M. Constanza Camargo
Stephanie J. Weinstein
Ana F. Best
Satu Männistö
Demetrius Albanes
Charles S. Rabkin
Publication date
01-09-2018
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 5/2018
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-018-0807-0

Other articles of this Issue 5/2018

Gastric Cancer 5/2018 Go to the issue

Original Article

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)

Original Article

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

Original Article

Which method is more suitable for advanced gastric cancer with enlarged lymph nodes, laparoscopic radical gastrectomy or open gastrectomy?

Original Article

Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication

Technical Note

Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS)

Original Article

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits